Category Features

Innovación y acceso: ¿Fisión o fusión? Entrevista a Tim Wilsdon, vicepresidente de CRA

Tomando como referencia el trabajo del Grupo de Alto Nivel de las Naciones Unidas sobre el Acceso a los Medicamentos, esta serie de artículos patrocinados invita a expertos en la materia a expresar sus puntos de vista sobre las políticas que respaldan con mayor eficacia la formulación de soluciones que respondan a los principales desafíos de las sociedades, y sobre cómo los entornos propicios para la implantación de políticas, incluidas las relativas a los sistemas de propiedad intelectual, influyen en el desarrollo y el caudal de nuevas tecnologías y servicios en diferentes sectores, campos tecnológicos y territorios. Las opiniones expresadas en los artículos son las de los autores. A continuación, presentamos la entrevista a Tim Wilsdon, vicepresidente de CRA.

Q&A With Erich Spangenberg On Patents And Drug Prices

Prices for drugs have long been a problem for developing countries but now have become out of reach for many in developed countries, sparking policy debates and efforts to address it. One of the top figures in the patent monetization business, industry maverick Erich Spangenberg offers a lively opinion on the underlying problem and how to fix it. To start? Stop granting patent extensions for minor changes.

Interview – Indigenous Concern Over Rising Focus On IP In WIPO TK Talks

Indigenous peoples have been the victims of repeated acts of biopiracy while the international community has failed to act to prevent it, indigenous representatives said in an interview this week. The World Intellectual Property Organization has been discussing ways to address that issue for some 16 years, without success. As negotiators continue to seek consensus on what a potential treaty could achieve, indigenous peoples feel the spotlight has drifted from their issues to technical issues of the intellectual property system and highlighted attention on users of the system.

Innovation And Access: Fission Or Fusion? Interview With Dr. Kristina M. Lybecker, Associate Professor Of Economics At Colorado College

In the light of the UN High-Level Panel on Access to Medicines, this series of sponsored articles challenges experts to give their views on the policies that best support the development of solutions to societies’ greatest challenges and how enabling policy environments, including IP systems, influence the development and flow of new technologies and services in different sectors, fields of technology, and jurisdictions. The views expressed in the articles are those of the authors. Below is an interview with Dr. Kristina M. Lybecker, Associate Professor of Economics at Colorado College in Colorado Springs (US).

Innovation et accès : fission ou fusion ? Entretien avec David Taylor, Professeur en Politique Pharmaceutique et de Santé Publique à l’UCL (University College London)

Dans le sillage du Groupe de Haut Niveau des Nations Unies sur l’accès aux médicaments (UN High-Level Panel on Access to Medicines) cette série d’articles sponsorisés convie des experts à donner leur point de vue sur les politiques les mieux à même de favoriser l’élaboration de solutions aux plus importants enjeux sociétaux, ainsi que sur la manière dont un cadre réglementaire favorable –y compris les systèmes de protection de la propriété intellectuelle – influence le développement et la diffusion de nouvelles technologies et de nouveaux services au sein de différents secteurs, domaines technologiques et juridictions. Les opinions exprimées dans ces articles n’engagent que leurs auteurs.

Innovación y acceso: ¿fisión o fusión? Entrevista a David Taylor, profesor de Políticas Farmacéuticas y de Salud Pública del University College de Londres

Tomando como referencia el trabajo del Grupo de Alto Nivel de las Naciones Unidas sobre el Acceso a los Medicamentos (UN High-Level Panel on Access to Medicines), esta serie de artículos patrocinados invita a expertos en la materia a expresar sus puntos de vista sobre las políticas que respaldan con mayor eficacia la formulación de soluciones que respondan a los principales desafíos de las sociedades, y sobre cómo los entornos propicios para la implantación de políticas, incluidas las relativas a los sistemas de propiedad intelectual, influyen en el desarrollo y el caudal de nuevas tecnologías y servicios en diferentes sectores, campos tecnológicos y territorios. Las opiniones expresadas en los artículos son las del autor.

Innovation And Access: Fission Or Fusion? Interview With Tim Wilsdon, CRA Vice President

In the light of the UN High-Level Panel on Access to Medicines, this series of sponsored articles challenges experts to give their views on the policies that best support the development of solutions to societies’ greatest challenges and how enabling policy environments, including IP systems, influence the development and flow of new technologies and services in different sectors, fields of technology, and jurisdictions. The views expressed in the articles are those of the authors. Below is an interview with Tim Wilsdon, Vice President, CRA.

US High Court To Consider IP Protection For Clothing Design

Fashion in the US generates over $330 billion in annual revenues, but it is more than a business. Fashion is a well-recognized art, displayed in numerous museum exhibitions throughout the world. This art, however, receives little IP protection in the US. But a case before the US Supreme Court could change that.

Guilty As Charged? Pakistan And The Special 301 Reports

Owais Hassan Shaikh writes: According to the section of US law on Special 301 reports, a country may be considered a priority foreign country even when it is fully compliant with the WTO Agreement on the Trade-Related Aspects of Intellectual Property Rights (TRIPS), the main multilateral agreement on IP rights today. Hence, this legislation and the determinations made in the Special 301 reports prioritize protection of commercial interests of the US nationals.

Can Patents Ever Be “Ever-Greened”? The Answer…They Are “Never-Greened”

“Ever-Greening of Patents” has been an expression that has been extensively used in debates related to the global pharmaceutical industry at least since the last two decades. Interestingly, this term has never been statutorily defined and hence has been applied most freely by professionals, policy makers and politicians alike. It would be appropriate to objectively examine whether patents in any jurisdiction can ever be “ever-greened”. A fitting initiation to this debate is the very concept of what a patent is from the very first principles, writes Prabuddha Ganguli.